论文部分内容阅读
高胆固醇血症作为冠心病(coronaryheartdisease,CHD)的重要危险因素已得到广泛的证实。降低血清胆固醇(TC)水平可降低CHD的患病率和病死率[1,2]。羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂是20世纪80年代中后期用于临床的强效调脂药,它能有效地降低TC和低密度脂蛋白胆固醇(LDL-C
Hypercholesterolemia as an important risk factor for coronary heart disease (coronary heart disease, CHD) has been widely confirmed. Lowering serum cholesterol (TC) can reduce the prevalence and mortality of CHD [1,2]. Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor is a potent lipid-lowering drug used clinically in the late 1980s. It can effectively reduce the levels of TC and low-density lipoprotein cholesterol (LDL-C